Prevention of cancer by prophylactic human papillomavirus vaccines

被引：24
|
作者：
Kwak, Kihyuck [1 ]
Yemelyanova, Anna [1 ]
Roden, Richard B. S. [1 ,2 ,3 ]
机构：
[1] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21231 USA
来源：
CURRENT OPINION IN IMMUNOLOGY | 2011年 / 23卷 / 02期
基金：
美国国家卫生研究院;
关键词：
VIRUS-LIKE PARTICLES; MINOR CAPSID PROTEIN; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; FUSION PROTEIN; DOUBLE-BLIND; YOUNG-WOMEN; L1; PROTEIN; HPV TYPES; B-CELL;
D O I：
10.1016/j.coi.2010.11.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Oncogenic human papillomaviruses (HPVs) are exclusively mucosal pathogens that are noncytopathic and the basal epithelial cells harboring and maintaining an infection do not produce either capsid antigen or virus. The efficacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several second generation vaccines aimed at expanding the coverage to all oncogenic HPV types and reducing barriers to global implementation. Currently there is no defined immune correlate of protection that can be used to determine if an individual patient is protected and for the evaluation of these second generation vaccines. Surprisingly, passive transfer of neutralizing serum antibody is protective in animal models. Recent studies suggest how neutralizing antibody mediates immunity against mucosal HPV and the possible impact of memory B cells.
引用
收藏
页码：244 / 251
页数：8
相关论文
共 50 条
  • [31] Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges
    Poljak, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 : 64 - 69
  • [32] Understanding and learning from the success of prophylactic human papillomavirus vaccines
    John T. Schiller
    Douglas R. Lowy
    Nature Reviews Microbiology, 2012, 10 : 681 - 692
  • [33] A Review of Prophylactic Human Papillomavirus Vaccines: Recommendations and Monitoring in the US
    Dunne, Eileen F.
    Datta, S. Deblina
    Markowitz, Lauri E.
    CANCER, 2008, 113 (10) : 2995 - 3003
  • [34] Understanding and learning from the success of prophylactic human papillomavirus vaccines
    Schiller, John T.
    Lowy, Douglas R.
    NATURE REVIEWS MICROBIOLOGY, 2012, 10 (10) : 681 - 692
  • [35] Human Papillomavirus, Cervical Cancer, and the Vaccines
    Miller, Ellen
    POSTGRADUATE MEDICINE, 2008, 120 (04) : 109 - 111
  • [36] Human papillomavirus vaccines for cervical cancer
    Murakami, M
    Gurski, KJ
    Steller, MA
    JOURNAL OF IMMUNOTHERAPY, 1999, 22 (03): : 212 - 218
  • [37] Human papillomavirus vaccines for cervical cancer
    Tindle, RW
    CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (05) : 643 - 650
  • [38] Cervical Cancer and Human Papillomavirus Vaccines
    Kim, Sunyoung
    Kwak, Jung-Im
    Song, Yun-Mi
    KOREAN JOURNAL OF FAMILY MEDICINE, 2008, 29 (11): : 821 - 830
  • [39] Human papillomavirus, cervical cancer, and the vaccines
    Tovar, John M.
    Bazaldua, Oralia V.
    Vargas, Leticia
    Reile, Erin
    POSTGRADUATE MEDICINE, 2008, 120 (02) : 79 - 84
  • [40] Development and Implementation of Papillomavirus Prophylactic Vaccines
    Frazer, Ian H.
    JOURNAL OF IMMUNOLOGY, 2014, 192 (09): : 4007 - 4011
12345